---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000062"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:09:21.496399+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports positive initial clinical data for inhaled gene therapies KB408 (AATD) and KB407 (CF)

## Summary
- KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.
- Gene delivery confirmed: 39% of airway cells AAT-positive post-dose vs 0% at baseline.
- KB407 for CF: Phase 1 CORAL-1 granted conditional sanctioning by CFF TDN; safe and well tolerated.
- KB407 enrolling Cohort 3 (4 daily doses); data expected 1H 2025.
- No serious adverse events in either program; all adverse events mild to moderate and transient.

## SEC filing metadata
- accession: 0001711279-24-000062
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000062/0001711279-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000062/krys-20241212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000062
- JSON: https://secwatch.observer/filing/0001711279-24-000062.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.